Biocon (BOM:532523) Cyclically Adjusted PB Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532523 Biocon Ltd BOM:532523
90 GF Score
Price ₹390.95
GF Value ₹332.72
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biocon Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocon  (BOM:532523) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biocon Cyclically Adjusted PB Ratio Related Terms


Biocon Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Biocon's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon Cyclically Adjusted PB Ratio Chart

Biocon Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.86 2.75 2.78 2.94 2.61

Biocon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.89 2.61 2.86 2.51 2.81

BOM:532523 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Biocon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocon's Cyclically Adjusted PB Ratio falls into.


BOM:532523
90GF Score
Biocon Ltd BOM:532523
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocon Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biocon's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Biocon's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=230.387/167.3573*167.3573
=230.387

Current CPI (Jun. 2026) = 167.3573.

Biocon Quarterly Data

Book Value per Share CPI Adj_Book
201609 39.570 105.961 62.498
201612 0.000 105.196 0.000
201703 43.448 105.196 69.122
201706 0.000 107.109 0.000
201709 44.591 109.021 68.451
201712 45.958 109.404 70.303
201803 47.075 109.786 71.761
201806 0.000 111.317 0.000
201809 51.576 115.142 74.965
201812 54.008 115.142 78.500
201903 55.891 118.202 79.134
201906 0.000 120.880 0.000
201909 58.547 123.175 79.548
201912 0.000 126.235 0.000
202003 61.526 124.705 82.569
202006 0.000 127.000 0.000
202009 65.202 130.118 83.863
202012 67.542 130.889 86.360
202103 70.897 131.771 90.044
202106 72.006 134.084 89.874
202109 73.522 135.847 90.576
202112 75.745 138.161 91.752
202203 78.877 138.822 95.091
202206 79.527 142.347 93.500
202209 90.286 144.661 104.451
202212 165.492 145.763 190.009
202303 187.313 146.865 213.450
202306 200.641 150.280 223.441
202309 202.211 151.492 223.388
202312 209.337 152.924 229.094
202403 210.518 153.035 230.221
202406 218.333 155.789 234.546
202409 222.555 157.882 235.911
202412 229.594 158.323 242.695
202503 230.822 157.552 245.188
202506 239.333 159.755 250.722
202509 247.241 162.289 254.962
202512 254.412 163.281 260.764
202603 226.127 164.272 230.373
202606 230.387 167.357 230.387

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biocon (BOM:532523) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹390.95 is trading 17.5% above its estimated GF Value™ of ₹332.72. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for BOM:532523:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹332.72 vs. price of ₹390.95 (17.5% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the BOM:532523 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocon Business Description

Other Exchanges BIOCON:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
90GF Score

Get the complete analysis for BOM:532523

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹390.95
Price
₹332.72
GF Value